细胞免疫疗法-话题@MedSci

#细胞免疫疗法#

25篇内容 | 965人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1476326, encodeId=851114e632629, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=NK细胞免疫疗法惹争议，新型疗法何去何从？, objectType=article, longId=210320, objectId=e49f21032049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e49f21032049, replyNumber=0, likeNumber=36, createdTime=2021-04-24, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e49f21032049, moduleTitle=NK细胞免疫疗法惹争议，新型疗法何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e49f21032049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476325, encodeId=861e14e6325be, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, objectType=article, longId=205468, objectId=b398205468c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398205468c7, replyNumber=0, likeNumber=58, createdTime=2021-01-09, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398205468c7, moduleTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b398205468c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476324, encodeId=2eb514e6324c1, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, objectType=article, longId=202609, objectId=56f8202609e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f8202609e1, replyNumber=0, likeNumber=36, createdTime=2020-10-31, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f8202609e1, moduleTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f8202609e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476323, encodeId=87a714e6323cc, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, objectType=article, longId=200586, objectId=adbc20058698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adbc20058698, replyNumber=0, likeNumber=36, createdTime=2020-09-13, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adbc20058698, moduleTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adbc20058698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476322, encodeId=405614e632218, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点, objectType=article, longId=200189, objectId=f76d20018958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f76d20018958, replyNumber=0, likeNumber=35, createdTime=2020-09-05, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f76d20018958, moduleTitle=Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f76d20018958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476321, encodeId=5aff14e6321dc, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, objectType=article, longId=198778, objectId=f56d198e7883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f56d198e7883, replyNumber=0, likeNumber=45, createdTime=2020-08-07, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f56d198e7883, moduleTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f56d198e7883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476320, encodeId=b2f814e6320ad, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=“巨噬细胞免疫疗法”CT-0508治疗实体瘤：优于传统细胞疗法, objectType=article, longId=198167, objectId=ae3e19816ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae3e19816ef3, replyNumber=0, likeNumber=39, createdTime=2020-07-29, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae3e19816ef3, moduleTitle=“巨噬细胞免疫疗法”CT-0508治疗实体瘤：优于传统细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae3e19816ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476319, encodeId=8c5f14e6319c7, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症, objectType=article, longId=194508, objectId=fb54194508d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb54194508d4, replyNumber=0, likeNumber=43, createdTime=2020-05-23, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb54194508d4, moduleTitle=重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb54194508d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476318, encodeId=f36814e63185f, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, objectType=article, longId=192035, objectId=9c5119203548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5119203548, replyNumber=0, likeNumber=44, createdTime=2020-04-13, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5119203548, moduleTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c5119203548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476317, encodeId=a84414e63174c, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, objectType=article, longId=191240, objectId=fac619124043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fac619124043, replyNumber=0, likeNumber=63, createdTime=2020-04-03, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fac619124043, moduleTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fac619124043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476316, encodeId=31dc14e6316fa, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, objectType=article, longId=184677, objectId=6ed31846e733, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed31846e733, replyNumber=0, likeNumber=50, createdTime=2019-12-14, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed31846e733, moduleTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed31846e733)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476315, encodeId=441314e63154a, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=37, createdTime=2019-06-28, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476314, encodeId=849b14e631498, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=李宗海：“死磕”肿瘤，让细胞免疫疗法悬壶济世, objectType=article, longId=168056, objectId=902e1680567c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902e1680567c, replyNumber=0, likeNumber=50, createdTime=2019-06-12, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902e1680567c, moduleTitle=李宗海：“死磕”肿瘤，让细胞免疫疗法悬壶济世, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902e1680567c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476313, encodeId=530f14e63136a, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=专家“亿”周谈——聚焦高危慢性淋巴细胞白血病：靶向药物与细胞免疫疗法, objectType=article, longId=154556, objectId=1abd15455646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1abd15455646, replyNumber=0, likeNumber=35, createdTime=2018-11-30, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1abd15455646, moduleTitle=专家“亿”周谈——聚焦高危慢性淋巴细胞白血病：靶向药物与细胞免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1abd15455646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476312, encodeId=14a214e63126e, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。, objectType=article, longId=117241, objectId=458d11e2415b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=458d11e2415b, replyNumber=0, likeNumber=39, createdTime=2017-10-25, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=458d11e2415b, moduleTitle=Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=458d11e2415b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476311, encodeId=ad2614e631148, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。, objectType=article, longId=116944, objectId=9e6111694445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e6111694445, replyNumber=0, likeNumber=37, createdTime=2017-10-22, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e6111694445, moduleTitle=Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e6111694445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476310, encodeId=b5b014e631083, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=CAR-T不行的“实体瘤”，巨噬细胞免疫疗法有了“新战绩”, objectType=article, longId=105890, objectId=4db210589030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4db210589030, replyNumber=0, likeNumber=42, createdTime=2017-07-20, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4db210589030, moduleTitle=CAR-T不行的“实体瘤”，巨噬细胞免疫疗法有了“新战绩”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4db210589030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476309, encodeId=b37814e6309a1, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！, objectType=article, longId=95128, objectId=155295128ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155295128ed, replyNumber=0, likeNumber=36, createdTime=2017-04-09, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155295128ed, moduleTitle=T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=155295128ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476308, encodeId=44f714e630830, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=【两会】凌锋教授：魏则西事件不应成为细胞免疫疗法的终止符, objectType=article, longId=91624, objectId=c19f916248a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c19f916248a, replyNumber=0, likeNumber=31, createdTime=2017-03-15, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c19f916248a, moduleTitle=【两会】凌锋教授：魏则西事件不应成为细胞免疫疗法的终止符, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c19f916248a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476327, encodeId=55eb14e63277d, content=<a href='/topic/show?id=e5d5e779600' target=_blank style='color:#2F92EE;'>#细胞免疫疗法#</a>, objectTitle=嵌合抗原受体T（CAR-T）细胞免疫疗法的风险与回报, objectType=article, longId=88742, objectId=e66488e4287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e66488e4287, replyNumber=0, likeNumber=48, createdTime=2017-02-15, rootId=0, userName=dzx0922891, userId=1b707274309, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e66488e4287, moduleTitle=嵌合抗原受体T（CAR-T）细胞免疫疗法的风险与回报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e66488e4287)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞免疫疗法

2020-05-29

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

NK细胞免疫疗法惹争议，新型疗法何去何从？

2021-04-24

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》

2021-01-09

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

CAR-T细胞免疫疗法临床研究与伦理审查实践

2020-10-31

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果

2020-09-13

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点

2020-09-05

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？

2020-08-07

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

“巨噬细胞免疫疗法”CT-0508治疗实体瘤：优于传统细胞疗法

2020-07-29

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症

2020-05-23

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物

2020-04-13

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤

2020-04-03

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定

2019-12-14

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-06-28

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

李宗海：“死磕”肿瘤，让细胞免疫疗法悬壶济世

2019-06-12

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

专家“亿”周谈——聚焦高危慢性淋巴细胞白血病：靶向药物与细胞免疫疗法

2018-11-30

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。

2017-10-25

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。

2017-10-22

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

CAR-T不行的“实体瘤”，巨噬细胞免疫疗法有了“新战绩”

2017-07-20

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！

2017-04-09

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

【两会】凌锋教授：魏则西事件不应成为细胞免疫疗法的终止符

2017-03-15

dzx0922891 (审核中...)

前往app查看评论内容

#细胞免疫疗法#

嵌合抗原受体T（CAR-T）细胞免疫疗法的风险与回报

2017-02-15

科室
- - 订阅+
  - 更多科室
工具
服务